Health Canada Updates the Multi-Vitamin/Mineral Supplements Monograph: Key Changes for NPN Applicants

Health Canada published the updated Multi-Vitamin/Mineral Supplements Monograph on April 24, 2026. This marks the first medium update to this monograph since 2015. This update is crucial for companies preparing, submitting, or maintaining Natural Product Number (NPN) applications for products containing vitamins, minerals, and related combination ingredients. The revised monograph includes updates to medicinal ingredients, source information, claims, duration of use, risk statements, and labelling expectations.

For applicants, the 2026 version should be reviewed carefully. This is especially important for products already under development, currently in the submission process, or being assessed for label and claim compliance.

Clarification for Class II and Class III Occasional-Use Products

One of the most practical updates in the 2026 monograph is the new clarification for Class II and Class III products recommended for occasional use only. In the past, products involving occasional-use ingredients or occasional-use positioning, such as certain Class II products containing melatonin, often had to be assessed using more general guidance. Applicants were generally expected to avoid claims that suggested ongoing maintenance or support of good or general health. However, the monograph did not provide a clear list of acceptable Multi-Vitamin/Mineral Supplement claims for these types of products.

The updated monograph now adds Appendix IX, which clearly lists Multi-Vitamin/Mineral Supplement claims that may be acceptable for products recommended for occasional use only. This provides clearer boundaries for applicants when developing claim strategies for products that contain vitamins and/or minerals but are not intended to be positioned as traditional daily multivitamin or mineral supplements.

Key Ingredient and Claim Updates

Applications already submitted or products currently under development may need to be reviewed if they involve any of the following updates.

Nicotinamide Mononucleotide (NMN)

Nicotinamide mononucleotide (NMN) has been newly added to the monograph. This is a significant update for applicants working with products positioned around cellular energy, healthy aging, NAD+ support, or related product concepts. Because NMN is now addressed directly in the monograph, applicants should review whether the product’s medicinal ingredient listing, source information, dose, claim strategy, duration of use, and risk information align with the 2026 version.

Vitamin B6 Risk Statement Requirements

The 2026 update also introduces new risk statement considerations for Vitamin B6, especially at 10 mg per day or above. This is particularly relevant for multivitamin products, B-complex formulas, men’s and women’s multivitamins, energy support products, and nervous system support products, as Vitamin B6 is commonly included at meaningful levels in these formulations. Applicants should confirm whether the total daily intake of Vitamin B6 from the product triggers additional risk statement requirements under the updated monograph.

Additional Nervous System Support Claims

The updated monograph also includes additional nervous system support claims for:

• Thiamine

• Vitamin B6

• Vitamin B12

• Vitamin C

• Magnesium

  
  

This may provide additional claim opportunities for products containing these ingredients. However, applicants should continue to ensure that claims are framed within the permitted scope of the monograph. Claims should not imply treatment, prevention, or mitigation of diseases or conditions unless specifically supported through the appropriate application pathway.

Other Notable Updates

In addition to the major updates above, the 2026 monograph also includes several technical and structural changes that may affect product assessments and applications. These include updates related to:

• Niacin / niacinamide / NMN combination rules

• Potassium classification

• Folate / folic acid conversion expectations

• Silicon claim placement

  
  

While these updates may appear technical, they can affect how an application is prepared, how the formula is assessed, and how claims or dose information are presented on the Product Licence Application and product label.

Why This Matters for Applicants

For applicants preparing or already filing NPN applications under the Multi-Vitamin/Mineral Supplements Monograph, the 2026 update may affect several key areas of regulatory review, including:

• Formula assessment

• Medicinal ingredient classification

• Source ingredient acceptability

• Claim strategy

• Daily dose calculations

• Duration of use

• Risk wording

• Product Facts Table and label compliance

  
  

Products that were prepared based on the previous 2023 version of the monograph may require reassessment before submission or before responding to Health Canada information requests.

Recommended Next Steps

Companies with vitamin/mineral products in development or under review should compare their current formula, claims, dosage, duration of use, and label wording against the April 24, 2026 version of the monograph. Particular attention should be paid to products containing NMN, higher-dose Vitamin B6, nervous system support claims, folate/folic acid, potassium, silicon, and niacin/niacinamide combinations. A timely review can help identify whether updates are needed before submission, during an active review, or as part of future label and compliance maintenance.

Conclusion

In conclusion, the updated Multi-Vitamin/Mineral Supplements Monograph is a significant development for businesses in the health and veterinary product industries. The changes outlined in this update will help streamline the application process and ensure compliance with Health Canada's regulations. By staying informed and adapting to these updates, companies can enhance their product offerings and navigate the regulatory landscape more effectively.